Comparison of commercial and in-house real-time PCR assays for quantification of Epstein-Barr virus (EBV) DNA in plasma

BMC Microbiology

Volumn 7, Issue , 2007, Pages

  Perandin, Francesca ^a   Cariani, Elisabetta ^a   Pollara, Caterina Patrizia ^a   Manca, Nino ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ANIMAL CELL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DNA DETERMINATION; EPSTEIN BARR VIRUS; HUMAN; NONHUMAN; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; VIRUS DETECTION; VIRUS LOAD; VIRUS TITRATION; CALIBRATION; CELL LINE; GENETICS; METHODOLOGY; PLASMA; POLYMERASE CHAIN REACTION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARD; VIROLOGY; VIRUS INFECTION;

HUMAN HERPESVIRUS 4;

CALIBRATION; CELL LINE; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; PLASMA; POLYMERASE CHAIN REACTION; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 34247200961     PISSN: 14712180     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-7-22     Document Type: Article

References (28)

1. Detection and quantification of latently infected B lymphocytes in Epstein-Barr virus-seropositive, healthy individuals by polymerase chain reaction. HJ Wagner G Bein A Bitsch H Kirchner, J Clin Microbiol 1992 30 2826 2829 1333480
2. Epstein-Barr virus and oncogenesis: from latent genes to tumors. LS Young PG Murray, Oncogene 2003 22 5108 5121 10.1038/sj.onc.1206556 12910248
3. Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma. JM Timms A Bell JR Flavell PG Murray AB Rickinson A Traverse-Glehen F Berger HJ Delecluse, Lancet 2003 361 217 223 10.1016/S0140-6736(03)12271-4 12547545
4. EBV DNA in biopsies of Burkitt tumors and anaplastic carcinomas of the nasopharynx. H zur Hausen H Schulte-Holthausen G Klein W Henle G Henle P Clifford L Santesson, Nature 1970 228 1056 1058 10.1038/2281056a0 4320657
5. Epstein-Barr virus and gastric carcinoma. T Osato S Imai, Seminar Cancer Biol 1996 7 175 182 10.1006/scbi.1996.0024
6. Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. DT Rowe S Webber EM Schauer J Reyes M Green, Transplant Infect Dis 2001 3 79 87 10.1034/j.1399-3062. 2001.003002079.x
7. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. H Kimura K Nishikawa Y Hoshino A Sofue Y Nishiyama T Morishima, J Clin Microbiol 1999 37 132 136 9854077
8. Quantification of Epstein-Barr virus load in peripheral blood of human immunodeficiency virus-infected patients using real-time PCR. A Dehee C Asselot T Piolot C Jacomet W Rozenbaum M Vidaud A Garbarg-Chenon JC Nicolas, J Med Virol 2001 65 543 552 10.1002/jmv.2071 11596092
9. Routine use of real-time quantitative PCR for laboratory diagnosis of Epstein-Barr virus infection. K Brengel-Pesce P Morand A Schmuc MJ Bourgeat M Buisson G Bargues M Bouzid JM Seigneurin, J Med Virol 2002 66 360 369 10.1002/jmv.2153 11793388
10. Real-time quantitative PCR of Epstein-Barr virus BZLF1 DNA using the LightCycler. S Patel M Zuckerman M Smith, J Virol Methods 2003 109 227 233 10.1016/S0166-0934(03)00076-4 12711067
11. Comparison of commercial real-time PCR assays for quantification of Epstein-Barr virus DNA. G Ruiz P Pilar F De Ory JE Echevarrìa, J Clin Microbiol 2005 43 2053 2057 15872221 10.1128/JCM.43.5.2053-2057.2005
12. Comparison of a LightCycler-based real-time PCR for quantitation of Epstein-Barr viral load in different clinical specimens with semiquantitative PCR. A Krumbholz A Meerbach R Zell B Gruhn A Henke E Birch-Hirschfeld P Wutzler, J Med Virol 2006 78 598 607 10.1002/jmv.20581 16555269
13. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. HJ Wagner M Wessel W Jabs F Smets L Fischer G Offner P Bucsky, Transplantation 2001 72 1012 1019 10.1097/00007890-200109270-00006 11579293
14. Development of a real-time quantitative assay for detection of Epstein-Barr virus. HG Niester J van Esser E Fries KC Wolthers J Cornelissen AD Osterhaus, J Clin Microbiol 2000 38 712 715 10655372
15. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. SJ Stevens EA Verschuuren I Pronk W van Der Bij MC Harmsen TH The CJ Meijer AJ van Den Brule JM Middeldorp, Blood 2001 97 1165 1171 10.1182/blood.V97.5.1165 11222357
16. Epstein-Barr virus reactivation is a frequent event after allogenic hematopoietic stem cell transplantation and quantitatively predicts EBV-lymphoproliferative disease following T-cell depleted stem cell transplantation. JW van Esser JB van der Holt E Meijer HGM Niester R Trenschel SFT Thijsen, Blood 2001 98 972 978 10.1182/blood.V98.4.972 11493441
17. Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. MK Gandhi E Lambley J Burrows U Dua S Elliot PJ Shaw MH Prince M Wolf K Clarke C Underhill T Mills P Mollee D Gill P Mollee D Gill P Marlton JF Seymour R Khanna, Clin Cancer Res 2006 12 460 464 10.1158/1078-0432.CCR-05-2008 16428487
18. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. W-Y Au A Pang C Choy C-S Chim Y-L Kwong, Blood 2004 104 243 249 10.1182/blood-2003-12-4197 15031209
19. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. KCA Chan J Zhang ATC Chan KIK Lei S-F Leung LYS Chan KCK Chow YMD Lo, Cancer Res 2003 63 2028 2032 12727814
20. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. YMD Lo AT Chan LY Chan SF Leung CW Lam DP Huang PJ Johnson, Cancer Res 2000 60 6878 6881 11156384
21. Comparison study of different PCR assays in measuring circulating plasma Epstein-Barr virus DNA levels in patients with nasopharyngeal carcinoma. T Le CD Jones T-K Yau HA Shirazi PH Wong N Thomas BK Patterson AWM Lee JL Zehnder, Cancer Res 2005 11 5700 5707 10.1158/1078-0432.CCR-05-0648
22. Real-time PCR for mRNA quantitation. ML Wong JF Medrano, BioTechniques 2005 39 1 13
23. Assessment of automated DNA extraction coupled with real-time PCR for measuring Epstein-Barr virus load in whole blood, peripheral mononuclear cells and plasma. S Fafi-Kremer K Bregel-Pesce G Bargues MJ Bourgeat JM Seigneurin P Morand, J Clin Virol 2004 30 157 164 10.1016/j.jcv.2003.10.002 15125872
24. Evaluation of commercial real-time PCR assay for quantification of Epstein-Barr virus DNA in different groups of patients. S Kozic A Vince JI B es OD Rode SZ Lepej M Poljak M Bozic HH Kessler, J Virol Meth 2006 135 263 268 10.1016/j.jviromet.2006.03.013
25. A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Meijerink C Mandigers L Van de Locht E Tonnissen F Goodsaid J Raemaekers, J M D 2001 3 55 61
26. Summary results QCMD 2003 Epstein-Barr virus proficiecy programme. HGM Niester, Quality control for Molecular Diagnostics, Glasgow, United Kingdom 2004
27. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. KP Wandinger W Jabs A Siekhaus S Bubel P Trillenberg HJ Wagner K Wessel H Kirchner H Hennig, Neurology 2000 55 178 184 10908887
28. Persistence of human T cell lymphotropic virus type 1 (HTLV-1) sequences in peripheral blood mononuclear cells from patients with mycosis fungoides. N Manca E Piacentini M Gelmi P Calzavara MA Manganoni A Glukhov F Gargiulo M de Francesco F Pirali G de Panfilis A Turano, J Exp Med 1994 180 1973 1978 10.1084/jem.180.5.1973 7964473